Araştırma Makalesi

A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma

Cilt: 15 Sayı: 1 9 Mart 2021
PDF İndir
TR EN

A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma

Öz

Objective: Obesity is an important health concern all around the world and considered in relation to a number of comorbidities. In this study, we aimed to evaluate the incidence of renal angiomyolipoma (AML) in obese patients. Method: This retrospective study included 288 obese patients, who were followed up at the Obesity Center of the University of Health Sciences, Antalya Training and Research Hospital between 01/11/2018 and 01/02/2020. The laboratory parameters and the reports of the abdominal ultrasound scans (USG) taken when the patients first presented to our unit were all reviewed. The patients were divided into two groups: those with and without renal AML based on the abdominal USG reports, and were compared in terms of serum hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), erythrocyte count (RBC), blood urea nitrogen (BUN), creatinine and uric acid levels. Results: Of the patients, 93.05% were female and 6.94% were male. The mean age was 51.91±9.31 (21-73) years, the average body mass index (BMI) was 36.4 (30-65.19) kg/m2. Ten patients (3.47%) had renal AML found on the abdominal USG imaging reports. While the incidence of renal AML in the general population is reported to be 0.13%-0.44%, it was found 3.47% in our study with obese patients. Conclusion:The incidence of renal AML is increasing in obese patients. Associated with many comorbidities, obesity may also constitute a risk factor for renal AML. In order to determine the relationship between obesity and AML, more studies are needed with multi-centered and broader scopes.

Anahtar Kelimeler

Destekleyen Kurum

There is no support.

Teşekkür

We would like to thank Başak OĞUZ YOLCULAR for all the support she provided in the statistical analysis process of this study.

Kaynakça

  1. 1. Kıyan E. Obezite ve akciğer. Türkiye Klinikleri Göğüs Hastalıkları-Özel Konular 2020; 13 (1), 94-98.
  2. 2. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism Clinical and Experimental 2019; 92: 6-10.
  3. 3. Türkiye Endokrinoloji ve Metabolizma Derneği Obezite tanı ve tedavi kılavuzu 2019. Available online at http://temd.org.tr/admin/uploads/tbl_kilavuz/ 20190506163904- 2019tbl_kilavuz5ccdcb9e5d.pdf. Accessed June 8, 2020.
  4. 4. Dixon JB. The effect of obesity on health outcomes. Molecular and cellular endocrinology, 2010; 316 (2), 104-108.
  5. 5. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity, 2020; 28 (7), 1200-1204.
  6. 6. Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. Journal of the National Cancer Institute, 2015; 107 (2), 1-14.
  7. 7. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. The Lancet Oncology, 2015; 16 (1), 36-46.
  8. 8. World Cancer Research Fund. Continuous Update Project Expert Report 2018. Available online at http://dietandcancerreport.org. Accessed July 8, 2020.

Ayrıntılar

Birincil Dil

İngilizce

Konular

İç Hastalıkları

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

9 Mart 2021

Gönderilme Tarihi

28 Eylül 2020

Kabul Tarihi

18 Aralık 2020

Yayımlandığı Sayı

Yıl 2021 Cilt: 15 Sayı: 1

Kaynak Göster

APA
Bulca Acar, A., & Nur Eke, R. (2021). A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma. Turkish Journal of Family Medicine and Primary Care, 15(1), 136-141. https://doi.org/10.21763/tjfmpc.800756
AMA
1.Bulca Acar A, Nur Eke R. A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma. TJFMPC. 2021;15(1):136-141. doi:10.21763/tjfmpc.800756
Chicago
Bulca Acar, Aysima, ve Remziye Nur Eke. 2021. “A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma”. Turkish Journal of Family Medicine and Primary Care 15 (1): 136-41. https://doi.org/10.21763/tjfmpc.800756.
EndNote
Bulca Acar A, Nur Eke R (01 Mart 2021) A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma. Turkish Journal of Family Medicine and Primary Care 15 1 136–141.
IEEE
[1]A. Bulca Acar ve R. Nur Eke, “A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma”, TJFMPC, c. 15, sy 1, ss. 136–141, Mar. 2021, doi: 10.21763/tjfmpc.800756.
ISNAD
Bulca Acar, Aysima - Nur Eke, Remziye. “A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma”. Turkish Journal of Family Medicine and Primary Care 15/1 (01 Mart 2021): 136-141. https://doi.org/10.21763/tjfmpc.800756.
JAMA
1.Bulca Acar A, Nur Eke R. A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma. TJFMPC. 2021;15:136–141.
MLA
Bulca Acar, Aysima, ve Remziye Nur Eke. “A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma”. Turkish Journal of Family Medicine and Primary Care, c. 15, sy 1, Mart 2021, ss. 136-41, doi:10.21763/tjfmpc.800756.
Vancouver
1.Aysima Bulca Acar, Remziye Nur Eke. A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma. TJFMPC. 01 Mart 2021;15(1):136-41. doi:10.21763/tjfmpc.800756

Sağlığın ve birinci basamak bakımın anlaşılmasına ve geliştirilmesine katkıda bulunacak yeni bilgilere sahip yazarların İngilizce veya Türkçe makaleleri memnuniyetle karşılanmaktadır.

Turkish Journal of Family Medicine and Primary Care © 2024 by Aile Hekimliği Akademisi Derneği is licensed under CC BY-NC-ND 4.0